Mycophenolate mofetil in dermatology

Mycophenolate mofetil (MMF) is the prodrug of mycophenolic acid (MPA), a medication used to treat psoriasis in the 1970S until side effects and the concern of carcinogenesis led to its discontinuation. The prodrug, MMF, emerged decades later in the transplant field. Dermatologists have since used MMF off-label to treat various inflammatory skin conditions, with most research concentrating on its use in psoriasis, autoimmune blistering disorders, dermatitides, and connective tissue disorders. The appeal of MMF is predicated upon its lymphocyte Specificity and consequent decreased toxicity profile. These attributes may make it a preferable treatment option. Its use in the field of dermatology is currently limited by a lack of randomized controlled trials, potential Unknown side effects, and cost of treatment. In reviewing both Current literature and Our own clinic records, MMF appears to be a promising therapeutic option for the treatment of cutaneous inflammatory diseases. (J Am Acad Dermatol 2009;60:183-99.)